Cancer Biotherapy and Radiopharmaceuticals最新文献

{"title":"Identification of a Vascular Endothelial Growth Factor Receptor-3 Binding Peptide TMVP1 for Enhancing Drug Delivery Efficiency and Therapeutic Efficacy Against Tumor Lymphangiogenesis.","authors":"Teng Cheng, Fei Li, Zhenzhong Zhang, Yuan Yuan, Ying Zhou, Xiaohua Zhu, Ling Xi, Qingjian Dong, Danfeng Luo, Xiangyi Ma, Liangsheng Fan","doi":"10.1089/cbr.2024.0119","DOIUrl":"10.1089/cbr.2024.0119","url":null,"abstract":"<p><p><b><i>Background:</i></b> Vascular endothelial growth factor receptor-3 (VEGFR-3) plays an indispensable role in lymphangiogenesis. Previous findings suggest that blocking the VEGFR-3 signaling pathway can inhibit lymph node metastasis effectively, thus reducing the incidence of distant metastasis. The development of new VEGFR-3-targeting drugs for early detection and effective treatments is, therefore, urgently required. <b><i>Methods:</i></b> <i>In vitro</i> biopanning of a phage-displayed peptide library was used to identify specific peptides binding to the extracellular domain of VEGFR-3. We obtained a novel VEGFR-3-targeting peptide, TMVP1 (LARGR). Our combined immunofluorescence and radiolabeling studies revealed that FITC-TMVP1 and ^99mTc-labeled TMVP1 specifically accumulated in VEGFR-3-positive lymphatic vessels of tumors after intravenous administration in tumor xenograft models <i>in vivo</i>. To enhance the therapeutic efficacy of anticancer drugs, TMVP1 was fused to a proapoptotic peptide, _D(KLAKLAK)². <b><i>Results:</i></b> The fusion peptide strongly inhibited tumor lymphangiogenesis <i>in vitro</i> and <i>in vivo</i> and specifically suppressed lung metastasis in a 4T1 breast cancer xenograft model. The accumulation of the TMVP1 in lymphatic vessels was specific. <b><i>Conclusions:</i></b> Our results suggest that TMVP1 is a potential therapeutic strategy for developing new diagnostic tracers or alternative anticancer agents for tumor lymphangiogenesis and lymphatic metastasis.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"196-209"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy Analysis of Bronchial Arterial Chemoembolization for Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis.","authors":"Jiayao Wang, Yahan Xu, Tao Wang","doi":"10.1089/cbr.2024.0141","DOIUrl":"10.1089/cbr.2024.0141","url":null,"abstract":"<p><p><b><i>Objective:</i></b> This study aims to comprehensively evaluated the efficacy and safety of bronchial arterial chemoembolization (BACE) in the treatment of advanced nonsmall cell lung cancer (NSCLC) through a meta-analysis of single-group rate, providing evidence-based guidance for clinical treatment. <b><i>Materials and Methods:</i></b> A systematic search was conducted in PubMed, the Cochrane Library, Embase, and Web of Science databases for relevant studies up to January 15, 2024. Inclusion criteria encompassed single-arm or multi-arm studies of nonrandomized controlled trials, observational studies, and single-arm studies in English language, focusing on NSCLC patients treated with BACE. Data extraction, quality assessment, and statistical analysis were performed following predefined protocols. <b><i>Results:</i></b> In total, 172 articles were initially retrieved, with 11 studies meeting the inclusion criteria. The included studies comprised 510 patients. Meta-analysis revealed significant heterogeneity among studies for median progression-free survival (PFS), median overall survival (OS), objective response rate, and disease control rate. The combined median PFS was 6.87 months (95% confidence interval [CI] 5.30-8.44), and the combined median OS was 13.68 months (95% CI 10.69-16.67). Subgroup analysis based on intervention measures demonstrated varying efficacy outcomes. Adverse reactions associated with BACE were generally mild, with no reports of grade 3 or higher adverse events. <b><i>Conclusion:</i></b> BACE emerges as a promising treatment modality for advanced NSCLC, exhibiting favorable efficacy and safety profiles.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"161-172"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"IL-21 and IL-33 May Be Effective Biomarkers to Predict the Efficacy of PD-1 Monoclonal Antibody for Advanced Cholangiocarcinoma\".","authors":"Hinpetch Daungsupawong, Viroj Wiwanitkit","doi":"10.1089/cbr.2025.0039","DOIUrl":"https://doi.org/10.1089/cbr.2025.0039","url":null,"abstract":"","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline ¹⁸F-FDG PET Radiomics Predicting Therapeutic Efficacy of Diffuse Large B-Cell Lymphoma after R-CHOP (-Like) Therapy.","authors":"Fenglian Jing, Xinchao Zhang, Yunuan Liu, Xiaolin Chen, Xinming Zhao, Xiaoshan Chen, Huiqing Yuan, Meng Dai, Na Wang, Jingya Han, Jingmian Zhang","doi":"10.1089/cbr.2024.0115","DOIUrl":"10.1089/cbr.2024.0115","url":null,"abstract":"<p><p><b><i>Objective:</i></b> This study aimed to predict therapeutic efficacy among diffuse large B-cell lymphoma (DLBCL) after R-CHOP (-like) therapy using baseline ¹⁸F-fluorodeoxyglucose positron emission tomography (¹⁸F-FDG PET) radiomics. <b><i>Methods:</i></b> A total of 239 patients with DLBCL were enrolled in this study, with 82 patients having refractory/relapsed disease. The radiomics signatures were developed using a stacking ensemble approach. The efficacy of the radiomics signatures, the National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI), conventional PET parameters model, and their combinations in assessing refractory/relapse risk were evaluated using receiver operating characteristic (ROC) curves, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy and decision curve analysis. <b><i>Results:</i></b> The stacking model, along with the integrated model that combines stacking with the NCCN-IPI and SD_max (the distance between the two lesions farthest apart, normalized to the patient's body surface area), showed remarkable predictive capabilities with a high area under the curve (AUC), sensitivity, specificity, PPV, NPV, accuracy, and significant net benefit of the AUC (NB-AUC). Although no significant differences were observed between the combined and stacking models in terms of the AUC in either the training cohort (AUC: 0.992 vs. 0.985, <i>p</i> = 0.139) or the testing cohort (AUC: 0.768 vs. 0.781, <i>p</i> = 0.668), the integrated model exhibited higher values for sensitivity, PPV, NPV, accuracy, and NB-AUC than the stacking model. <b><i>Conclusion:</i></b> Baseline PET radiomics could predict therapeutic efficacy in DLBCL after R-CHOP (-like) therapy, with improved predictive performance when incorporating clinical features and SD_max.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"114-121"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of Radiosynthesis and First in-Human Dosimetry of ⁶⁸Ga-NOTA-UBI-29-41: A Proof of Concept Study.","authors":"Parul Thakral, Nishant Rana, Navneet Singh, Subha Shankar Das, Mrinalini Koley, Jatin Gupta, Dharmender Malik, Ishita Sen","doi":"10.1089/cbr.2024.0082","DOIUrl":"10.1089/cbr.2024.0082","url":null,"abstract":"<p><p><b><i>Background:</i></b> Antimicrobial peptides (AMPs) such as UBI-29-41 offer a distinctive approach for precise detection due to their unique interactions with bacteria and makes them promising candidates for specific and selective imaging. The study was aimed to corroborate the in-house manual synthesis of ⁶⁸Ga-NOTA-UBI-29-41, evaluate its uptake in patients with suspected infection, and estimate of patient-specific dosimetry to ensure optimal clinical application. <b><i>Materials and Methods:</i></b> ⁶⁸Ga-NOTA-UBI-29-41 was synthesized by using a variable amount of UBI-29-41 (60-90 μg) to 555 MBq of ⁶⁸Ga in 0.05 M hydrochloric acid (HCl) and heating the reaction sample for 12 min at 90°C at pH: 3.5-4 to obtain the radiopeptide with high yield and high radiochemical purity (RCP). ⁶⁸Ga-NOTA-UBI-29-41 positron emission tomography/computed tomography (PET/CT) scans at variable timepoints were done to evaluate its biodistribution and maximum uptake time. Furthermore, patient-specific dosimetric estimation was done using the HERMES software. <b><i>Results:</i></b> A total of 5 μg/37 MBq (5 μg/mCi) of NOTA-UBI-29-41 for 12 min at 90°C were the optimal parameters to obtain 88%-90% of yield and 98%-99 % of RCP. ⁶⁸Ga-NOTA-UBI-29-41 showed expeditious blood clearance and high renal excretion. The optimal time for imaging of infection with ⁶⁸Ga-NOTA-UBI-29-41 was found to be at 60 min postinjection (<i>n</i> = 8). The critical organ was the urinary bladder, receiving an average dose of 138.02 ± 45.92 µSv/MBq, followed by 53.81 ± 13.72 µSv/MBq for kidneys with a mean effective dose of 1.52 ± 0.64 mSv. <b><i>Conclusion:</i></b> The protocol for in-house manual labeling of ⁶⁸Ga-NOTA-UBI-29-41 was reproducible, providing high yield and RCP. ⁶⁸Ga-NOTA-UBI-29-41 administration was found to be safe and nontoxic. The favorable biodistribution and the first-in-human patient-specific dosimetry ensure optimal clinical application.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"104-113"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human-Artificial Intelligence Symbiotic Reporting for Theranostic Cancer Care.","authors":"J Harvey Turner","doi":"10.1089/cbr.2024.0216","DOIUrl":"10.1089/cbr.2024.0216","url":null,"abstract":"<p><p>Reporting of diagnostic nuclear images in clinical cancer management is generally qualitative. Theranostic treatment with ¹⁷⁷Lu radioligands for prostate cancer and neuroendocrine tumors is routinely given as the same arbitrary fixed administered activity to every patient. Nuclear oncology, as currently practiced with ¹⁷⁷Lu-prostate-specific membrane antigen and ¹⁷⁷Lu peptide receptor radionuclide therapy, cannot, therefore, be characterized as personalized precision medicine. The evolution of artificial intelligence (AI) could change this \"one-size-fits-all\" approach to theranostics, through development of a symbiotic relationship with physicians. Combining quantitative data collection, collation, and analytic computing power of AI algorithms with the clinical expertise, empathy, and personal care of patients by their physician envisions a new paradigm in theranostic reporting for molecular imaging and radioligand treatment of cancer. Human-AI interaction will facilitate the compilation of a comprehensive, integrated nuclear medicine report. This holistic report would incorporate radiomics to quantitatively analyze diagnostic digital imaging and prospectively calculate the radiation absorbed dose to tumor and critical normal organs. The therapy activity could then be accurately prescribed to deliver a preordained, effective, tumoricidal radiation absorbed dose to tumor, while minimizing toxicity in the particular patient. Post-therapy quantitative imaging would then validate the actual dose delivered and sequential pre- and post-treatment dosimetry each cycle would allow individual dose prescription and monitoring over the entire course of theranostic treatment. Furthermore, the nuclear medicine report would use AI analysis to predict likely clinical outcome, predicated upon AI definition of tumor molecular biology, pathology, and genomics, correlated with clinical history and laboratory data. Such synergistic comprehensive reporting will enable self-assurance of the nuclear physician who will necessarily be deemed personally responsible and accountable for the theranostic clinical outcome. Paradoxically, AI may thus be expected to enhance the practice of phronesis by the nuclear physician and foster a truly empathic trusting relationship with the cancer patient.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"89-95"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[⁶⁸Ga]Ga-FAPI04 Outperforms [¹⁸F]FDG PET/CT for Detecting Nodal Metastasis of Head and Neck Squamous Cell Carcinoma: A Single-Center Experience.","authors":"Serkan Kuyumcu, Emine Göknur Isik, Cömert Şen, Duygu Has-Şimsek, Bora Başaran, Zeynep Gözde Özkan, Fikret Büyükkaya, Yasemin Şanlı","doi":"10.1089/cbr.2024.0112","DOIUrl":"10.1089/cbr.2024.0112","url":null,"abstract":"<p><p>This study assesses fibroblast activated protein inhibitor (FAPI) targeted PET/CT imaging against [¹⁸F]FDG PET/CT (FDG PET) for detecting nodal involvement in head and neck squamous cell carcinoma (HNSCC), intending to improve diagnostic precision for metastatic lymph nodes and lay the groundwork for future investigations. <b><i>Methods:</i></b> Patients diagnosed with HNSCC were retrospectively enrolled. All patients underwent [⁶⁸Ga]Ga-FAPI04 PET/CT (FAPI PET) and FDG PET within 6 d. Primary tumor, lymph nodes, and tracer uptake were visually and quantitatively compared. The metastatic lymph nodes were evaluated using patient-and lesion-based analyses, with biopsy or postoperative histopathological examination as the reference. <b><i>Results:</i></b> The cohort includes 24 patients (17 men, 7 women; mean age 60 ± 11.8 years) who underwent FDG and FAPI PET for preoperative diagnostic workup or restaging due to known recurrence of HNSCC. Lesions included 24 primary tumors, 54 cervical lymph nodes, and 5 metastases. Primary tumors exhibited significant uptake on both PET modalities (median maximum standardized uptake value [SUV_max]: FDG 19.4 ± 11.6, FAPI 16.9 ± 4.6), with no statistically significant difference (<i>p</i> > 0.5). For lymph nodes, FAPI and FDG PET showed median SUV_max of 9.18 ± 6.77 and 9.67 ± 6.5, respectively. The patient-based analysis found FDG PET sensitivity at 88.2% and FAPI PET at 94.1%, with FAPI PET specificity significantly higher (85.7% vs. 42.8% for FDG PET). Lesion-based analysis revealed FAPI PET sensitivity and specificity at 84.2% and 93.7%, respectively, contrasting FDG PET's at 81.5% and 25%, respectively. <b><i>Conclusion:</i></b> This study underscores the efficacy of FAPI PET in detecting primary tumors in HNSCC. Furthermore, FAPI PET shows improved specificity over FDG PET for metastatic lymph nodes advocating further investigations for integrating FAPI PET into HNSCC clinical protocols for its enhanced precision in detecting metastatic lymph nodes.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"122-129"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142513373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledgment of Reviewers 2024.","authors":"","doi":"10.1089/cbr.2024.48720.revack","DOIUrl":"https://doi.org/10.1089/cbr.2024.48720.revack","url":null,"abstract":"","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":"40 2","pages":"151-152"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Same-Day Positron Emission Tomography/Computed Tomography with ⁶⁸Ga-Radiolabeled Fibroblast Activation Protein Inhibitors and ¹⁸F-Fluorodeoxyglucose Imaging for Gastrointestinal Cancers.","authors":"Xiaoshan Chen, Yunuan Liu, Xinming Zhao, Fenglian Jing, Bin Wang, Xiaolin Chen, Xiao Pang, Jingmian Zhang, Jianfang Wang, Zhaoqi Zhang, Jingya Han, Mengjiao Wang","doi":"10.1089/cbr.2024.0182","DOIUrl":"10.1089/cbr.2024.0182","url":null,"abstract":"<p><p><b><i>Objective:</i></b> We investigated the clinical practicability of same-day ⁶⁸Ga-radiolabeled fibroblast activation protein inhibitors (⁶⁸Ga-FAPI)-first and ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) imaging and compared it with same-day ¹⁸F-FDG-first or 2-day procedures in diagnosing gastrointestinal cancers. <b><i>Materials and Methods:</i></b> Sixty-five patients with confirmed gastrointestinal cancers were divided into same-day ⁶⁸Ga-FAPI-first group (Group A), same-day ¹⁸F-FDG-first group (Group B), and 2-day group (Group C). Low-dose CT and low injection activity were performed on ⁶⁸Ga-FAPI positron emission tomography/computed tomography (PET/CT). Interval times, radiation dose, diagnostic performance, and detectability were assessed among groups. Additionally, the uptake, tumor-to-liver ratio (TLR), diagnostic efficacy, and TNM stage were compared between the two modalities. <b><i>Results:</i></b> The total waiting time for Group C was significantly longer than that for Group A or B (both <i>p</i> < 0.001). The total dose-length product and effective dose decreased in all groups. There were comparable detectability and diagnostic performance among groups (all <i>p</i> > 0.05). The within-group analysis in Group B indicated that ⁶⁸Ga-FAPI PET/CT had higher uptake in the primary and recurrent lesions than ¹⁸F-FDG without differences in TLR, due to higher liver background on ⁶⁸Ga-FAPI PET than Group A or C (both <i>p</i> < 0.001).⁶⁸Ga-FAPI PET/CT possessed higher accuracy than ¹⁸F-FDG and changed staging in 14 patients (14/65, 21.54%). <b><i>Conclusions:</i></b> The same-day ⁶⁸Ga-FAPI-first and ¹⁸F-FDG imaging reduced examination waiting time without increased radiation dose, simultaneously achieving excellent diagnostic performance and improving clinical staging in diagnosing gastrointestinal cancers.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"130-138"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142513374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stratification of Lung Adenocarcinoma Patients Based on <i>In Silico</i> and Immunohistochemistry Analyses of Oxidative Stress-Related Genes.","authors":"Chongrong Qiu, Yuming Zhou, Xiaoliu Xiao, Tianjun Song, Dongyun Zeng, Jingliang Peng","doi":"10.1089/cbr.2024.0094","DOIUrl":"10.1089/cbr.2024.0094","url":null,"abstract":"<p><p><b><i>Background:</i></b> Lung adenocarcinoma (LUAD) remains heterogeneous in the prognosis of patients; oxidative stress (OS) has been widely linked to cancer progression. Therefore, it is necessary to explore the prognostic value of the OS-associated genes in LUAD. <b><i>Methods:</i></b> An OS-associated prognostic signature was developed using the Cox regression and random forest model in The Cancer Genome Atlas-LUAD dataset. Kaplan-Meier <b>(K-M)</b> survival curve and time-dependent receiver operating characteristic (tROC) curves were applied to evaluate and validate the predictive accuracy of this signature among the training and testing cohorts. A nomogram was constructed and also verified by the concordance index (C-index), calibration curves, and tROC curves, respectively. ESTIMATE algorithm and CIBERSORT algorithms were conducted to explore the signature's immune characteristics. Core target genes of the prognostic signature were identified in the protein-protein interaction network. <b><i>Results:</i></b> A six OS-associated prognostic gene signature (<i>CDC25C, ERO1A, GRIA1, TERT, CAV1, BDNF</i>) was developed. The tROC and K-M survival curves in the training and testing cohorts revealed that the signature had good and robust predictive capability to predict the overall survival of LUAD patients. Meanwhile, the risk score was an independent prognostic factor influencing patients' overall survival. The results of the C-index (0.714), calibration curves, and the 1-, 2-, and 3-year tROC curves (area under the curve = 0.703, 0.737, and 0.723, respectively) suggested that the nomogram had good predictive efficacy and prognostic value for LUAD. Then, the authors found that the high-risk group may be depletion or loss of antitumor function of immune cells. Finally, 10 core genes of the signature were predicted. <b><i>Conclusion:</i></b> Their study may provide a novel understanding for the identification of prognostic stratification in LUAD patients, as well as the regulation of OS-associated genes in LUAD progression.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"11-21"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141478034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}